Skip to main content

Table 2 Summary and comparison of [68Ga]Ga-DOTA-TOC PET/CT results

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

VariableWhole patients (n = 31)No previous treatment (n = 15)Previous treatment (n = 16)p value
Krenning score (2/3/4)3/6/221/4/102/2/120.562
Median tumour-to-liver ratio (TLR)8.1 (1.0–36.9)6.5 (1.7–36.9)10.9 (1.0–36.1)0.299
Median maximum standardized uptake value (SUVmax)42.9 (5.9–180.1)50.7 (6.8–180.1)63.0 (5.9–143.1)0.446
Median whole tumour volume (WTV, cm3)58.9 (0.0–617.7)71.2 (0.0–617.7)26.1 (0.0–219.5)0.216
Median total receptor expression (TRE)778.5 (0.0–9694.0)1186.1 (0.0–9694.0)687.2 (0.0–5007.3)0.188
Mean liver mean SUV (SUVmean)5.5 ± 1.7 (2.8–9.3)5.4 ± 1.7 (2.8–9.3)5.6 ± 1.7 (2.8–8.6)0.626
  1. PET positron emission tomography, CT computed tomography